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RESPONSE TO LETTER
Response to “Influence
of Diabetes on
Antiplatelet Drug
Efficacy”
Aleksi Tornio1,
Colin N.A. Palmer2 and
Alex S.F. Doney3
To The Editor: Gong et al. in their Letter
to the Editor make valuable comments in
relation to our study, which, as they cor-
rectly point out, included a substantial
number of individuals with diabetes. First,
they draw attention to the well-
documented increased platelet reactivity in
patients with diabetes, and a recent study
showing increased platelet P2Y12 expres-
sion may be contributory. They also high-
light a recent fairly small study indicating
that in stroke patients the CYP2C19 loss-
of-function allele had a reduced impact on
clopidogrel response in individuals with
higher glycated albumin levels independent
of diabetes status. Such observations imply
reduced efﬁcacy of clopidogrel in this
patient population. Indeed, a further study
indicates impaired P2Y12 inhibition by clo-
pidogrel in individuals with diabetes is
largely mediated by its reduced metabo-
lism.1 Second, they allude to studies indi-
cating that obese subjects and smokers also
have a prothrombotic state and that in
smokers this may also be associated with
increased platelet P2Y12. Smokers, how-
ever, may have an increased clopidogrel
responsiveness2 through induction of
CYP2C19, although more recent work has
indicated that the impact of smoking on
clopidogrel responsiveness is abrogated
when accounting for hemoglobin levels.3
Our study comprised a bioresource
linked to electronic medical records. In
essence, we conducted a Mendelian-
randomized prospective observational
study of the clinical impact of CYP2C19
loss-of-function genotype in a population
of individuals who had all redeemed pre-
scriptions for clopidogrel following hospi-
talization for an arterial thrombo-occlusive
event. As a consequence, we are not able to
directly compare the overall efﬁcacy of clo-
pidogrel therapy with a comparator arm to
investigate the impact of diabetes and
related features. However, it is possible to
exploit CYP2C19 genotype as a genetic
instrument to probe the extent to which
these features modify antiplatelet response.
Our overall study comprised 72% individu-
als with diabetes and 77% of the outcome
events occurred in this group. While we
found that diabetes, obesity, smoking, and
recent elevated glycated hemoglobin were,
as expected, signiﬁcantly associated with
increased risk, we did not ﬁnd any evidence
of an interaction with the CYP2C19 geno-
type. While we probably do not have ade-
quate power in our current study to
formally avoid a type II error, a meta-
analysis of clinical trials also found no sub-
stantial effect of either diabetes or obesity
on clopidogrel efﬁcacy.4 Our bioresource is
currently expanding with the Scottish-wide
GoSHARE study (www.goshare.org.uk).
As a consequence, we anticipate the ability
to explore these interesting and highly clin-
ical relevant aspects in the future.
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